Trial Outcomes & Findings for Mild Cognitive Impairment and Obstructive Sleep Apnea (NCT NCT01482351)
NCT ID: NCT01482351
Last Updated: 2019-03-06
Results Overview
Memory (immediate and delayed recall) will be assessed using HVLT-R. HVLT-R has been used in elders with Alzheimer's Disease and takes 10 minutes to complete. Total score ranges from 0 to 60, a higher score indicates a better memory (better outcome).
COMPLETED
NA
54 participants
Change from baseline at 6 months and 1 year
2019-03-06
Participant Flow
From 9/2012 to 12/2014, study investigators identified potential participants from clinical practices, advertisements in newspapers, clinical trials registries, senior centers, advertisements in public transportation centers, the Alzheimer's Association, and support groups.
Participant milestones
| Measure |
Experimental: MCI/OSA/CPAP Adherent and Non-adherent
All participants were diagnosed with MCI and OSA. The diagnostic criteria for OSA was defined as an AHI score greater than or equal to 10. CPAP was prescribed for nightly use. At baseline there were 68 participants had OSA (AHI ≥10). 14 persons withdrew prior to 6 month testing. There were 54 active MCI participants with OSA at 6 months and 12 month: 29 were CPAP adherent and 25 were CPAP non-adherent.
|
|---|---|
|
Overall Study
STARTED
|
68
|
|
Overall Study
6 Months
|
54
|
|
Overall Study
12 Months
|
54
|
|
Overall Study
COMPLETED
|
54
|
|
Overall Study
NOT COMPLETED
|
14
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Only 45 of the 54 participants provided income data.
Baseline characteristics by cohort
| Measure |
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
Total
n=54 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
67.4 years
STANDARD_DEVIATION 7.2 • n=29 Participants
|
73.2 years
STANDARD_DEVIATION 8.6 • n=25 Participants
|
70.1 years
STANDARD_DEVIATION 8.3 • n=54 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=29 Participants
|
15 Participants
n=25 Participants
|
24 Participants
n=54 Participants
|
|
Sex: Female, Male
Male
|
20 Participants
n=29 Participants
|
10 Participants
n=25 Participants
|
30 Participants
n=54 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=29 Participants
|
0 Participants
n=25 Participants
|
0 Participants
n=54 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=29 Participants
|
1 Participants
n=25 Participants
|
2 Participants
n=54 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=29 Participants
|
0 Participants
n=25 Participants
|
0 Participants
n=54 Participants
|
|
Race (NIH/OMB)
Black or African American
|
4 Participants
n=29 Participants
|
13 Participants
n=25 Participants
|
17 Participants
n=54 Participants
|
|
Race (NIH/OMB)
White
|
24 Participants
n=29 Participants
|
11 Participants
n=25 Participants
|
35 Participants
n=54 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=29 Participants
|
0 Participants
n=25 Participants
|
0 Participants
n=54 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=29 Participants
|
0 Participants
n=25 Participants
|
0 Participants
n=54 Participants
|
|
Region of Enrollment
United States
|
29 participants
n=29 Participants
|
25 participants
n=25 Participants
|
54 participants
n=54 Participants
|
|
Education
|
26 participants
n=29 Participants
|
21 participants
n=25 Participants
|
47 participants
n=54 Participants
|
|
Married/Cohabitate
|
23 participants
n=29 Participants
|
8 participants
n=25 Participants
|
31 participants
n=54 Participants
|
|
BMI
|
30.3 kg/m^2
STANDARD_DEVIATION 6.7 • n=29 Participants
|
29.5 kg/m^2
STANDARD_DEVIATION 6.5 • n=25 Participants
|
29.9 kg/m^2
STANDARD_DEVIATION 6.6 • n=54 Participants
|
|
Income - <$20,000
|
3 Participants
n=24 Participants • Only 45 of the 54 participants provided income data.
|
9 Participants
n=21 Participants • Only 45 of the 54 participants provided income data.
|
12 Participants
n=45 Participants • Only 45 of the 54 participants provided income data.
|
|
Income - $20,000 - $39,999
|
2 Participants
n=24 Participants • Only 45 of the 54 participants provided income data.
|
2 Participants
n=21 Participants • Only 45 of the 54 participants provided income data.
|
4 Participants
n=45 Participants • Only 45 of the 54 participants provided income data.
|
|
Income - $40,000 - $69,999
|
3 Participants
n=24 Participants • Only 45 of the 54 participants provided income data.
|
4 Participants
n=21 Participants • Only 45 of the 54 participants provided income data.
|
7 Participants
n=45 Participants • Only 45 of the 54 participants provided income data.
|
|
Income - $70,000 - $99,999
|
4 Participants
n=24 Participants • Only 45 of the 54 participants provided income data.
|
2 Participants
n=21 Participants • Only 45 of the 54 participants provided income data.
|
6 Participants
n=45 Participants • Only 45 of the 54 participants provided income data.
|
|
Income - >$100,000
|
12 Participants
n=24 Participants • Only 45 of the 54 participants provided income data.
|
4 Participants
n=21 Participants • Only 45 of the 54 participants provided income data.
|
16 Participants
n=45 Participants • Only 45 of the 54 participants provided income data.
|
|
Study Partner-Spouse/cohabitate
|
26 Participants
n=29 Participants
|
9 Participants
n=25 Participants
|
35 Participants
n=54 Participants
|
|
Study Partner-Adult child
|
1 Participants
n=29 Participants
|
6 Participants
n=25 Participants
|
7 Participants
n=54 Participants
|
|
Study Partner-Other
|
2 Participants
n=29 Participants
|
10 Participants
n=25 Participants
|
12 Participants
n=54 Participants
|
|
Reported/known conditions-Diabetes
|
7 Participants
n=29 Participants
|
8 Participants
n=25 Participants
|
15 Participants
n=54 Participants
|
|
Reported/known conditions-Cardiovascular Disease
|
11 Participants
n=29 Participants
|
14 Participants
n=25 Participants
|
25 Participants
n=54 Participants
|
|
Reported/known conditions-Hypertension
|
15 Participants
n=29 Participants
|
14 Participants
n=25 Participants
|
29 Participants
n=54 Participants
|
|
Apolipoprotein E (ApoE)-E2/E2
|
0 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
|
1 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
|
1 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
|
|
ApoE-E2/E3
|
1 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
|
0 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
|
1 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
|
|
ApoE-E2/E4
|
1 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
|
0 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
|
1 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
|
|
ApoE-E3/E3
|
16 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
|
18 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
|
34 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
|
|
ApoE-E3/E4
|
9 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
|
4 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
|
13 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
|
|
ApoE-E4/E4
|
0 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
|
2 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
|
2 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
|
|
Medications-Cholinesterase inhibitors
|
1 Participants
n=29 Participants
|
2 Participants
n=25 Participants
|
3 Participants
n=54 Participants
|
|
Medications-NMDA Receptor Antagonist
|
0 Participants
n=29 Participants
|
0 Participants
n=25 Participants
|
0 Participants
n=54 Participants
|
|
Medications-Opioid Analgesics
|
0 Participants
n=29 Participants
|
3 Participants
n=25 Participants
|
3 Participants
n=54 Participants
|
|
Medications-Antidepressants
|
6 Participants
n=29 Participants
|
1 Participants
n=25 Participants
|
7 Participants
n=54 Participants
|
|
Medications-Sedatives/anxiolytics
|
5 Participants
n=29 Participants
|
5 Participants
n=25 Participants
|
10 Participants
n=54 Participants
|
|
Medications-Antihypertensives
|
19 Participants
n=29 Participants
|
21 Participants
n=25 Participants
|
40 Participants
n=54 Participants
|
|
Medications-Cholesterol medications
|
21 Participants
n=29 Participants
|
18 Participants
n=25 Participants
|
39 Participants
n=54 Participants
|
|
MMSE
|
28.3 units on a scale
STANDARD_DEVIATION 1.4 • n=29 Participants
|
28.0 units on a scale
STANDARD_DEVIATION 2.1 • n=25 Participants
|
28.2 units on a scale
STANDARD_DEVIATION 1.7 • n=54 Participants
|
|
CDR
|
0.5 units on a scale
STANDARD_DEVIATION 0.3 • n=29 Participants
|
0.7 units on a scale
STANDARD_DEVIATION 0.7 • n=25 Participants
|
0.6 units on a scale
STANDARD_DEVIATION 0.5 • n=54 Participants
|
|
ESS
|
8.5 units on a scale
STANDARD_DEVIATION 3.5 • n=29 Participants
|
9.3 units on a scale
STANDARD_DEVIATION 5.3 • n=25 Participants
|
8.9 units on a scale
STANDARD_DEVIATION 4.4 • n=54 Participants
|
|
BDI-II
|
7.7 units on a scale
STANDARD_DEVIATION 4.6 • n=29 Participants
|
6.4 units on a scale
STANDARD_DEVIATION 6.6 • n=25 Participants
|
7.1 units on a scale
STANDARD_DEVIATION 5.6 • n=54 Participants
|
|
ARES - Total sleep time
|
441.0 minutes
STANDARD_DEVIATION 107.0 • n=29 Participants
|
334.2 minutes
STANDARD_DEVIATION 35.6 • n=25 Participants
|
374.3 minutes
STANDARD_DEVIATION 84.0 • n=54 Participants
|
|
ARES - Apnea-Hypopnea Index
|
21.3 events/hour
STANDARD_DEVIATION 7.8 • n=29 Participants
|
14.6 events/hour
STANDARD_DEVIATION 2.7 • n=25 Participants
|
17.1 events/hour
STANDARD_DEVIATION 5.8 • n=54 Participants
|
|
ARES - Lowest oxygen saturation
|
83.6 percentage of blood oxygen saturation
STANDARD_DEVIATION 4.3 • n=29 Participants
|
82.9 percentage of blood oxygen saturation
STANDARD_DEVIATION 2.8 • n=25 Participants
|
83.1 percentage of blood oxygen saturation
STANDARD_DEVIATION 3.1 • n=54 Participants
|
|
PSG - Total sleep time
|
283.2 minutes
STANDARD_DEVIATION 84.0 • n=29 Participants
|
270.5 minutes
STANDARD_DEVIATION 95.9 • n=25 Participants
|
279.0 minutes
STANDARD_DEVIATION 86.7 • n=54 Participants
|
|
PSG - Apnea-Hypopnea Index
|
25.3 events/hour
STANDARD_DEVIATION 11.5 • n=29 Participants
|
31.1 events/hour
STANDARD_DEVIATION 20.8 • n=25 Participants
|
27.2 events/hour
STANDARD_DEVIATION 15.0 • n=54 Participants
|
|
PSG - Lowest oxygen saturation
|
82.3 percentage of blood oxygen saturation
STANDARD_DEVIATION 6.9 • n=29 Participants
|
81.8 percentage of blood oxygen saturation
STANDARD_DEVIATION 5.0 • n=25 Participants
|
82.2 percentage of blood oxygen saturation
STANDARD_DEVIATION 6.3 • n=54 Participants
|
|
Split-night PSG - Total sleep time
|
218.2 minutes
STANDARD_DEVIATION 150.6 • n=29 Participants
|
150.4 minutes
STANDARD_DEVIATION 77.4 • n=25 Participants
|
166.1 minutes
STANDARD_DEVIATION 95.7 • n=54 Participants
|
|
Split-night PSG - Apnea-Hypopnea index
|
25.6 events/hour
STANDARD_DEVIATION 9.2 • n=29 Participants
|
14.6 events/hour
STANDARD_DEVIATION 7.8 • n=25 Participants
|
17.7 events/hour
STANDARD_DEVIATION 9.4 • n=54 Participants
|
|
Split-night PSG - Lowest oxygen saturation
|
86.0 percentage of blood oxygen saturation
STANDARD_DEVIATION 5.0 • n=29 Participants
|
82.9 percentage of blood oxygen saturation
STANDARD_DEVIATION 6.3 • n=25 Participants
|
83.8 percentage of blood oxygen saturation
STANDARD_DEVIATION 6.0 • n=54 Participants
|
PRIMARY outcome
Timeframe: Change from baseline at 6 months and 1 yearPopulation: 14 participants lost to follow-up prior to 6-months testing.
Memory (immediate and delayed recall) will be assessed using HVLT-R. HVLT-R has been used in elders with Alzheimer's Disease and takes 10 minutes to complete. Total score ranges from 0 to 60, a higher score indicates a better memory (better outcome).
Outcome measures
| Measure |
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
|---|---|---|
|
Hopkins Verbal Learning Test-Revised (HVLT-R)
Baseline
|
23.52 score on a scale
Standard Deviation 5.56
|
20.04 score on a scale
Standard Deviation 5.30
|
|
Hopkins Verbal Learning Test-Revised (HVLT-R)
6-month
|
23.68 score on a scale
Standard Deviation 5.08
|
20.39 score on a scale
Standard Deviation 5.48
|
|
Hopkins Verbal Learning Test-Revised (HVLT-R)
1 year
|
23.59 score on a scale
Standard Deviation 5.73
|
20.82 score on a scale
Standard Deviation 5.69
|
PRIMARY outcome
Timeframe: Change from baseline at 6 months and 1 yearPopulation: 14 participants lost to follow-up prior to 6-months testing.
The Digit Symbol subtest (DS) from the Wechsler Adult Intelligence Scale (WAIS-R) was used to measure psychomotor/cognitive processing speed. An age-adjusted total scaled score was used for analysis. The adjusted total score ranges from -5.7 to+27. A higher score indicates a better outcome.
Outcome measures
| Measure |
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
|---|---|---|
|
Digit Symbol Subtest (DS)
Baseline
|
9.18 score on a scale
Standard Deviation 2.59
|
8.06 score on a scale
Standard Deviation 2.65
|
|
Digit Symbol Subtest (DS)
6-months
|
9.90 score on a scale
Standard Deviation 2.74
|
8.02 score on a scale
Standard Deviation 2.36
|
|
Digit Symbol Subtest (DS)
1 year
|
10.21 score on a scale
Standard Deviation 3.03
|
8.09 score on a scale
Standard Deviation 2.78
|
PRIMARY outcome
Timeframe: Change from baseline at 6 months and 1 yearPopulation: 14 participants lost to follow-up prior to 6-months testing.
Global cognitive function will be assessed using MMSE. It is a 30-item cognitive screen measuring orientation, registration, short-term memory, attention/concentration, language, and constructional capacity. Summary score will be used as a measure of global cognitive function. Total score ranges from 0 to 30, equal to and above 24 is normal (better outcome), less than 21 indicates increasing odds of dementia (worse outcome).
Outcome measures
| Measure |
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
|---|---|---|
|
Mini Mental State Evaluation Exam (MMSE)
Baseline
|
28.34 score on a scale
Standard Deviation 1.40
|
28.00 score on a scale
Standard Deviation 2.10
|
|
Mini Mental State Evaluation Exam (MMSE)
6-month
|
28.61 score on a scale
Standard Deviation 1.62
|
27.48 score on a scale
Standard Deviation 2.00
|
|
Mini Mental State Evaluation Exam (MMSE)
1-year
|
27.93 score on a scale
Standard Deviation 2.05
|
26.43 score on a scale
Standard Deviation 2.46
|
PRIMARY outcome
Timeframe: Change from baseline at 6 months and 1 yearPopulation: 14 participants were lost to follow-up prior to 6-months testing.
Attention will be measured using SCW. We used the Golden and Freshwater's (2002) version. This version provides paper stimuli for each trial: in the first, columns of the words"red""blue" and "green" are printed in black ink (Word Reading; W); in the second, columns of the same words are printed in red, blue, or green ink (Color Naming; C); in the third, the words "red" "blue" and "green" are printed in a colored ink (red, blue or green) that does not match the word (Color-Word; CW). Participants read each page aloud as quickly as possible for 45 seconds and receive a score for each trial representing the number of items correctly read aloud. The Interference T-score is obtained by first calculating a deviation score by subtracting a predicted CW score from the obtained raw CW score (in 45s). The obtained deviation score is then converted to an Interference T-score. Lower T scores(T\<40) in the Interference condition show reductions in inhibitory control.
Outcome measures
| Measure |
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
|---|---|---|
|
Stroop Color and Word Test (SCW)
6-month
|
48.22 score on a scale
Standard Deviation 8.20
|
45.36 score on a scale
Standard Deviation 8.57
|
|
Stroop Color and Word Test (SCW)
Baseline
|
47.36 score on a scale
Standard Deviation 6.15
|
44.28 score on a scale
Standard Deviation 8.19
|
|
Stroop Color and Word Test (SCW)
1-year
|
50.00 score on a scale
Standard Deviation 7.40
|
45.14 score on a scale
Standard Deviation 9.47
|
PRIMARY outcome
Timeframe: Change from baseline at 6 months and 1 yearPopulation: 14 participants were lost to follow-up prior to 6-months testing.
Attention/reaction time will assessed using the PVT. The participants sat in a closed and quiet examination room, without any auditory or visual disturbance. A 1-minute mock PVT demonstration was done prior to each test. The PVT visual display was held 14-22 inches from the subject's eyes. The participants were asked to either use the index finger or thumb of their dominant hand to respond to the PVT signals. The participants were instructed to maintain the fastest possible reaction times to a simple visual stimulus: a red light emitting diode displaying time in milliseconds in a window of the portable PVT device. We used number of lapses, defined as mean reaction time above 500 milliseconds (errors of omission) as the primary outcome. Lower score indicates better outcomes (Less lapses).
Outcome measures
| Measure |
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
|---|---|---|
|
The Psychomotor Vigilance Task (PVT)
6-month
|
2.58 score on a scale
Standard Deviation 1.64
|
4.29 score on a scale
Standard Deviation 2.71
|
|
The Psychomotor Vigilance Task (PVT)
Baseline
|
3.09 score on a scale
Standard Deviation 1.53
|
6.46 score on a scale
Standard Deviation 3.66
|
|
The Psychomotor Vigilance Task (PVT)
1-year
|
2.77 score on a scale
Standard Deviation 1.91
|
4.76 score on a scale
Standard Deviation 2.94
|
PRIMARY outcome
Timeframe: Change from baseline at 6 months and 1 yearPopulation: 14 participants were lost to follow-up prior to 6-months testing.
Daytime sleepiness be assessed using ESS. The ESS asks the respondent to rate the likelihood of falling asleep in eight specific situations using a four-point Likert scale ranging from never dozing to high chance of dozing. The scale significantly correlates with the frequency of apneas and is a clinical and research standard for the assessment of daytime sleepiness. The total score ranges from 0 to 24, a higher score indicates higher chance of daytime sleepiness (worse outcome).
Outcome measures
| Measure |
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
|---|---|---|
|
Epworth Sleepiness Scale [ESS]
1-year
|
6.34 score on a scale
Standard Deviation 3.71
|
7.57 score on a scale
Standard Deviation 4.37
|
|
Epworth Sleepiness Scale [ESS]
Baseline
|
8.50 score on a scale
Standard Deviation 3.52
|
9.32 score on a scale
Standard Deviation 5.34
|
|
Epworth Sleepiness Scale [ESS]
6-months
|
6.54 score on a scale
Standard Deviation 3.17
|
8.00 score on a scale
Standard Deviation 5.53
|
SECONDARY outcome
Timeframe: Change from baseline at 6 months and 1 yearPopulation: 14 participants were lost to follow-up prior to 6-months testing.
Everyday function will be assessed using FOSQ. It is a 30-item Likert-scale, self-report, disease-specific functional status measure written at the 4th grade level. The total score ranges from 0 to 120, a higher score indicates a better outcome.
Outcome measures
| Measure |
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
|---|---|---|
|
Functional Outcomes Sleep Questionnaire (FOSQ)
Baseline
|
17.31 score on a scale
Standard Deviation 1.99
|
17.34 score on a scale
Standard Deviation 2.66
|
|
Functional Outcomes Sleep Questionnaire (FOSQ)
6-month
|
18.17 score on a scale
Standard Deviation 1.48
|
18.13 score on a scale
Standard Deviation 2.14
|
|
Functional Outcomes Sleep Questionnaire (FOSQ)
1-year
|
18.30 score on a scale
Standard Deviation 1.82
|
18.63 score on a scale
Standard Deviation 1.95
|
SECONDARY outcome
Timeframe: Change from baseline at 6 months and 1 yearPopulation: 14 participants were lost to follow up prior to 6 months testing.
This informant-rated composes of multiple subscales, to evaluate cognitively based functional abilities in older adults. The factor structure of Everyday Cognition was assessed with confirmatory factor analysis, which supported a 7-factor model including 1 global factor and 6 domain-specific factors (Everyday Memory, Language, Visuospatial Abilities, Planning, Organization, and Divided Attention). The total mean score ranges from 0 to 57. A higher score indicates a worse outcome.
Outcome measures
| Measure |
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
|---|---|---|
|
Everyday Function Outcome: Everyday Cognition (E-Cog)
Baseline
|
1.46 score on a scale
Standard Deviation 0.54
|
1.29 score on a scale
Standard Deviation 0.41
|
|
Everyday Function Outcome: Everyday Cognition (E-Cog)
6 months
|
1.35 score on a scale
Standard Deviation 0.36
|
1.43 score on a scale
Standard Deviation 0.52
|
|
Everyday Function Outcome: Everyday Cognition (E-Cog)
1-year
|
1.35 score on a scale
Standard Deviation 0.51
|
1.52 score on a scale
Standard Deviation 0.70
|
SECONDARY outcome
Timeframe: Change from baseline at 1 yearPopulation: Participants who completed the study and improved on ADCS-CGIC scores at 1year adjusted for age, race and marital status.
Global change (progression) will be assessed using ADCS-CGIC at 1 year. It has 8 categories as markedly improved, moderately improved, minimally improved, not changed, minimally worse, moderately worse, markedly worse, missing response.
Outcome measures
| Measure |
MCI/OSA/CPAP Adherent
n=41 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
MCI/OSA/CPAP Non-adherent
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
|---|---|---|
|
Alzheimer's Disease Cooperative Study - Clinicians' Global Impression of Change Scale (ADCS-CGIC)
ADCS-CGIC Improved
|
34 participants
|
—
|
|
Alzheimer's Disease Cooperative Study - Clinicians' Global Impression of Change Scale (ADCS-CGIC)
ADCS-CGIC Unimproved
|
7 participants
|
—
|
SECONDARY outcome
Timeframe: Change from baseline at 1 yearPopulation: Study participants who completed the study and improved on CDR data adjusted for age, race and marital status.
Cognitive ability will be assessed and staged using CDR. It contains 6 items (memory, orientation, judgement and problem solving, community affairs, home and hobbies, personal care), and each item ranges from 0 to 3. The total score ranges from 0 to 18, a higher score indicates a worse outcome. We observed the change of CDR score from baseline to 1-year follow up. Improved on CDR was defined as a lower CDR score compared to baseline. Reference group is unimproved, defined as worsened (higher) CDR or unchanged CDR compared to baseline.
Outcome measures
| Measure |
MCI/OSA/CPAP Adherent
n=42 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
MCI/OSA/CPAP Non-adherent
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
|
|---|---|---|
|
Clinical Dementia Rating Scale (CDR)
CDR Improved
|
21 participants
|
—
|
|
Clinical Dementia Rating Scale (CDR)
CDR Unimproved
|
21 participants
|
—
|
Adverse Events
MCI/OSA/CPAP Adherent
MCI/OSA/CPAP Non-adherent
Serious adverse events
| Measure |
MCI/OSA/CPAP Adherent
n=29 participants at risk
Device: CPAP. Included those diagnosed with MCI and OSA. The diagnostic criteria for OSA was defined as an AHI score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
|
MCI/OSA/CPAP Non-adherent
n=25 participants at risk
Device: CPAP. Included those diagnosed with MCI and OSA. The diagnostic criteria for OSA was defined as an AHI score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
|
|---|---|---|
|
Cardiac disorders
Heart irregularities
|
6.9%
2/29 • Number of events 2 • 1 year
|
0.00%
0/25 • 1 year
|
|
General disorders
Hospital admission
|
3.4%
1/29 • Number of events 1 • 1 year
|
0.00%
0/25 • 1 year
|
|
Injury, poisoning and procedural complications
Bleeding
|
3.4%
1/29 • Number of events 1 • 1 year
|
0.00%
0/25 • 1 year
|
|
Musculoskeletal and connective tissue disorders
Surgery
|
3.4%
1/29 • Number of events 1 • 1 year
|
0.00%
0/25 • 1 year
|
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place